Floatz Rating
B58/100
Confidence
Indicative
Sponsor
Uppsala University
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
57High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06245629CT.gov Bortezomib-bendamustine-melphalan vs Melphalan for Multiple Myeloma | — | Recruiting | — | — | — |
NCT05182073CT.gov FT576 in Subjects With Multiple Myeloma | — | Completed | — | — | — |
NCT04674813CT.gov A Study of CC-95266 in Participants With Relapsed and/or Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT04762745CT.gov The Efficacy and Safety of Pomalidomide and Bendamustine With Dexamethasone in Relapsed or Refractory Multiple Myeloma | — | Unknown | — | — | — |
NCT04083898CT.gov Isatuximab, Bendamustine, and Prednisone in Refractory Multiple Myeloma | — | Terminated | — | — | — |
NCT03878524CT.gov Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial | — | Terminated | — | — | — |
NCT03997968CT.gov A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors | — | Completed | — | — | — |
NCT06400238CT.gov Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Expression (MATCH - Subprotocol Z1H) | — | Active Not Recruiting | — | — | — |
NCT03524235CT.gov Haploidentical Stem Cell Transplant with Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL | — | Completed | — | — | — |
NCT02477215CT.gov Study of Bendamustine and IXAZOMIB (MLN9708) Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma | — | Completed | — | — | — |
Show 18 more trialsShow fewer
NCT02465060CT.gov Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) | — | Active Not Recruiting | — | — | — |
NCT02237261CT.gov Bendamustine, Prednisone and Velcade® for First-line Treatment of Patients With Symptomatic Multiple Myeloma | — | Completed | — | — | — |
NCT02424851CT.gov Optimising Renal Outcome in Myeloma Renal Failure | — | Completed | — | — | — |
NCT02240719CT.gov Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic Cancer | — | Completed | — | — | — |
NCT02148913CT.gov Phase I: Melphalan, Bendamustine and Carfilzomib for Autologous Transplant in Multiple Myeloma | — | Completed | — | — | — |
NCT02095834CT.gov Carfilzomib, Bendamustine Hydrochloride, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT02002598CT.gov Carfilzomib With Bendamustine and Dexamethasone in Multiple Myeloma | — | Terminated | — | — | — |
NCT01754402CT.gov Bendamustine + Pomalidomide + Dex in R/R Multiple Myeloma | — | Unknown | — | — | — |
NCT01526694CT.gov Phase II Trial Designed to Determine Efficacy and Safety of Bendamustine+Dexamethasone+Thalidomide in R/R MM | — | Completed | — | — | — |
NCT01849848CT.gov Study of SyB L-0501 to Treat Relapsed/Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT01326702CT.gov Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors | — | Completed | — | — | — |
NCT01376401CT.gov Bendamustine, Bortezomib (Velcade ®) and Prednisone (BVP) in Patients Newly Diagnosed Multiple Myeloma | — | Completed | — | — | — |
NCT01332617CT.gov Phase II Study of Simvastatin for Relapsed/Refractory Myeloma | — | Withdrawn | — | — | — |
NCT01179490CT.gov Efficacy and Safety Study of SyB L-0501 for Patients With Multiple Myeloma | — | Terminated | — | — | — |
NCT01168804CT.gov Bendamustine Plus Bortezomib Plus Dexamethasone in Relapsed or Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT01045681CT.gov Study of Bendamustine, Velcade and Dexamethasone in the Treatment of Elderly Patients With Multiple Myeloma | — | Completed | — | — | — |
NCT01002703CT.gov Treatment With Lenalidomide, Bendamustine and Prednisone (RBP) in Patients With Relapsed or Refractory Multiple Myeloma | — | Unknown | — | — | — |
NCT01042704CT.gov Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Plasma Cell Myeloma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Bendamustine (this asset) | Uppsala University | P3 | B · 58 |
| Hyaluronidase Fihj | Massachusetts General Hospital | P4 | BBB |
| Filanesib | PETHEMA Foundation | P2 | BBB |
| Vincristine Sulfate | Roswell Park Cancer Institute | P3 | BBB |
| Cyclosporin A | Seoul National University Hospital | P3 | BBB |
| Anti-Human T-Lymphocyte Immunoglobulin, Rabbit | University of Birmingham | P4 | BBB |
| Epoetin Alfa | Mayo Clinic | P3 | BB |
| Arsenic Trioxide | Duke University | P2 | BB |
| Sorafenib | OHSU Knight Cancer Institute | P2 | BB |
+42 more in the Plasma Cell Myeloma cohort
Other indications for Bendamustine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Non-Hodgkin Lymphoma | — | P3 | BB · 70 |
| B-Cell Chronic Lymphocytic Leukemia | — | P3 | BB · 70 |
| Follicular Lymphoma | — | P4 | BB · 69 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Bendamustine in Plasma Cell Myeloma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/bendamustine-plasma-cell-myeloma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →